Today: 7 February 2026
Subscribe
Browse Category

Mergers and Acquisitions News 22 December 2025 - 31 December 2025

Abivax stock drops today as ABVX traders trim Eli Lilly takeover bets into year-end

Abivax stock drops today as ABVX traders trim Eli Lilly takeover bets into year-end

NEW YORK, December 31, 2025, 11:19 ET — Regular session Abivax Société Anonyme’s U.S.-listed American depositary shares (ABVX) fell about 3.8% to $133.04, down roughly $5.30 from Tuesday’s close, in late morning trade on Wednesday. The shares opened at $138 and swung between $132.13 and $140.25, with about 348,000 shares traded. The pullback keeps the spotlight on ABVX after takeover chatter earlier this month. Reuters reported on Dec. 10 that Abivax jumped on market rumours that Eli Lilly could make an offer, and Stifel analyst Damien Choplain said the “share price movement is driven by speculation around a possible takeover.”
31 December 2025
····
Coforge’s $2.35 billion Encora deal tops India’s stocks-to-watch list for Dec. 29

Coforge’s $2.35 billion Encora deal tops India’s stocks-to-watch list for Dec. 29

NEW YORK, December 28, 2025, 22:48 ET Indian stocks were set for a firmer start on Monday, with IT services firm Coforge in focus after it agreed to buy U.S.-based Encora in a deal valued at $2.35 billion on an enterprise-value basis, according to Moneycontrol. GIFT Nifty futures rose 40 points to 26,100, Upstox reported. Moneycontrol+1 The deal lands in the final stretch of year-end trading, when big corporate announcements can drive sharp moves in individual shares even if broader volumes thin out. Investors also had fresh catalysts ranging from stake sales to regulatory filings and contract wins. Moneycontrol+2Moneycontrol+2 Coforge,
29 December 2025
·····
Ondas Holdings (NASDAQ: ONDS) Stock News Today: Defense-Drone Contracts, M&A Momentum, and Fresh Analyst Targets in a Thin Holiday Market

Ondas Holdings (NASDAQ: ONDS) Stock News Today: Defense-Drone Contracts, M&A Momentum, and Fresh Analyst Targets in a Thin Holiday Market

As of 1:47 p.m. in New York on Friday, December 26, 2025, U.S. markets are open, but the tape is behaving like a post-holiday hallway: quieter than usual, with sudden echoes when a small-cap name trips an algorithm. Ondas Holdings Inc. (ONDS) is one of those echo-makers today. Shares are trading around $8.56, down roughly $0.57 (about -6%) on the session, after opening near $9.10 and printing an intraday range of about $8.55 to $9.18, with volume over 24 million shares. That downside move is happening against a mostly subdued broader market backdrop: large-cap ETFs are near flat-to-slightly-down (SPY), tech
26 December 2025
·····
Zeta Global (ZETA) Stock Today: Marigold Deal, AI-Agent Momentum, and Wall Street Targets as Markets Reopen After Christmas

Zeta Global (ZETA) Stock Today: Marigold Deal, AI-Agent Momentum, and Wall Street Targets as Markets Reopen After Christmas

NEW YORK — Friday, December 26, 2025 (10:17 a.m. ET).Zeta Global Holdings Corp. (NYSE: ZETA) is trading around $19.12 in late-morning action, essentially flat on the day after opening near $19.05, with early trading ranging roughly between $18.70 and $19.20. Today’s tape has the familiar post-holiday feel: U.S. stocks opened mixed as traders returned from the Christmas break, and volumes were widely expected to be lighter into year-end. AP News Seasonality watchers also point out that Dec. 26 has historically been one of the strongest calendar days for U.S. equities, though history is not a trade plan. MarketWatch For Zeta
26 December 2025
·····
AI Stocks Today (Dec. 25, 2025): Nvidia’s Groq Deal, Snowflake’s M&A Talks, UiPath’s Index Boost, and Meta’s WhatsApp AI Clash

AI Stocks Today (Dec. 25, 2025): Nvidia’s Groq Deal, Snowflake’s M&A Talks, UiPath’s Index Boost, and Meta’s WhatsApp AI Clash

December 25, 2025 — It’s Christmas Day, U.S. markets are taking a breather, and yet the AI-stock news cycle is doing what it always does: refusing to sleep. With investors digesting a holiday-thinned week of announcements, today’s biggest AI-stock narratives revolve around AI inference hardware, software consolidation, and regulatory pressure on AI distribution channels—the plumbing that decides which chatbots can reach billions of users. Below is what’s driving “AI stocks today” headlines on 25.12.2025, and why each item matters for 2026 positioning. Nvidia’s Groq licensing deal puts AI inference back in the spotlight The biggest AI-stock story dominating headlines into
25 December 2025
········
AI Stocks Today (Dec. 24, 2025, 5:02 p.m. ET): Nvidia’s Reported $20B Groq Deal, Snowflake M&A Talk, and Wall Street’s 2026 AI Outlook

AI Stocks Today (Dec. 24, 2025, 5:02 p.m. ET): Nvidia’s Reported $20B Groq Deal, Snowflake M&A Talk, and Wall Street’s 2026 AI Outlook

As of 5:02 p.m. ET on Wednesday, December 24, 2025, the “AI trade” is closing out a holiday-shortened session with fresh momentum — and a new set of questions investors can’t ignore. On one hand, U.S. benchmarks pushed to new records during the early Christmas Eve close, a classic “Santa rally” setup supported by easing-rate expectations and renewed appetite for mega-cap tech and AI names. On the other hand, today’s biggest AI headlines aren’t just about chips and models anymore. They’re increasingly about dealmaking, data-center financing, capital-expenditure transparency, and regulatory pressure on how AI assistants get distributed to consumers. Reuters+1
24 December 2025
·····
Dynavax Technologies (DVAX) Stock Jumps on Sanofi’s $2.2B Cash Buyout Offer: Latest News, Forecasts, and What Comes Next (Dec. 24, 2025)

Dynavax Technologies (DVAX) Stock Jumps on Sanofi’s $2.2B Cash Buyout Offer: Latest News, Forecasts, and What Comes Next (Dec. 24, 2025)

Dynavax Technologies Corporation (NASDAQ: DVAX) is the center of the biotech tape on Wednesday, December 24, 2025, after Sanofi announced a deal to acquire the vaccine maker in an all-cash transaction valued at roughly $2.2 billion. The headline number investors are keying on: $15.50 per share in cash—a bid that reframes the near-term outlook for DVAX stock from “earnings and pipeline execution” to “deal timeline and closing risk.” Sanofi+1 Below is what’s driving today’s move, how the market is pricing the deal so far, what Wall Street forecasts looked like before the announcement, and the key dates and risks investors
24 December 2025
······
Clearwater Analytics (CWAN) Stock News on Dec. 23, 2025: $24.55 Take-Private Deal, Go‑Shop Window, Analyst Reactions, and What Investors Should Watch

Clearwater Analytics (CWAN) Stock News on Dec. 23, 2025: $24.55 Take-Private Deal, Go‑Shop Window, Analyst Reactions, and What Investors Should Watch

Clearwater Analytics Holdings, Inc. (NYSE: CWAN) is trading like a classic merger-arbitrage stock on December 23, 2025—hovering just below the agreed buyout price after the company signed a definitive deal to go private. Shares recently changed hands around $24.06, closely tracking the $24.55-per-share all-cash acquisition price. The tight gap reflects a market that is largely pricing in deal completion, while still attaching some risk to timing, approvals, and the possibility—however slim—of a higher bid emerging during the “go-shop” period. Below is a full, news-style breakdown of what’s happening with Clearwater Analytics stock, what the buyout terms actually say, what analysts
23 December 2025
·····
Amicus Therapeutics (FOLD) Stock Today: BioMarin’s $14.50 Cash Buyout, Analyst Downgrades, and What Investors Watch Next (Dec. 22, 2025)

Amicus Therapeutics (FOLD) Stock Today: BioMarin’s $14.50 Cash Buyout, Analyst Downgrades, and What Investors Watch Next (Dec. 22, 2025)

Amicus Therapeutics, Inc. (NASDAQ: FOLD) is trading like a classic “deal stock” on December 22, 2025—hovering just below a fixed cash acquisition price after BioMarin Pharmaceutical (NASDAQ: BMRN) agreed to buy the company in an all-cash transaction. As of the latest available trade on Dec. 22, FOLD is around $14.22, with the market effectively pricing in the probability, timing, and risk of the merger closing—rather than the stand-alone upside of Amicus’ rare disease commercial portfolio. Below is a detailed roundup of the current news, forecasts, and analyst/market commentary shaping Amicus stock on 22.12.2025—and the specific catalysts that can still move
22 December 2025
······
ABIVAX Société Anonyme Stock (ABVX) Jumps on Fresh Eli Lilly Takeover Talk as Nasdaq Biotech Index Inclusion Takes EffectABIVAXABIVAX Société Anonyme Stock (ABVX) Jumps on Fresh Eli Lilly Takeover Talk as Nasdaq Biotech Index Inclusion Takes Effect

ABIVAX Société Anonyme Stock (ABVX) Jumps on Fresh Eli Lilly Takeover Talk as Nasdaq Biotech Index Inclusion Takes EffectABIVAXABIVAX Société Anonyme Stock (ABVX) Jumps on Fresh Eli Lilly Takeover Talk as Nasdaq Biotech Index Inclusion Takes Effect

PARIS / NEW YORK — December 22, 2025 — ABIVAX Société Anonyme (Abivax SA) stock is back in the spotlight on Monday after renewed takeover chatter tied to U.S. pharma giant Eli Lilly—arriving the same morning Abivax’s addition to the Nasdaq Biotechnology Index (NBI) becomes effective. The combination is fueling a sharp move in ABVX shares and re-igniting debate about whether 2025’s biotech breakout is now morphing into an M&A (mergers and acquisitions) story. What’s happening with ABIVAX stock today (December 22, 2025) Abivax shares rose sharply in Monday trading as media reports revived speculation that Eli Lilly could be
22 December 2025
··
ABIVAX (ABVX) Stock Surges on Eli Lilly Takeover Talk as Nasdaq Biotech Index Inclusion Kicks In — News, Forecasts and Outlook (Dec. 22, 2025)

ABIVAX (ABVX) Stock Surges on Eli Lilly Takeover Talk as Nasdaq Biotech Index Inclusion Kicks In — News, Forecasts and Outlook (Dec. 22, 2025)

December 22, 2025 — ABIVAX Société Anonyme (ticker ABVX on Nasdaq and Euronext Paris) is back in the spotlight today, with traders juggling two storylines that can move a biotech stock fast: renewed takeover speculation involving Eli Lilly and Abivax’s addition to the Nasdaq Biotechnology Index (NBI), effective before today’s market open. GlobeNewswire+2Investing.com+2 In early market action, multiple outlets reported double‑digit gains in Abivax’s U.S. premarket trading and strong moves in Paris, making ABVX one of the morning’s most-watched biotech tickers. Benzinga+2Investing.com+2 But the bigger reason ABIVAX stock keeps showing up in “top movers” lists isn’t just rumor-driven volatility. The
22 December 2025
·······
Amicus Therapeutics (FOLD) Stock Week Ahead: $14.50 BioMarin Buyout Puts the Deal Spread—and New Filings—Front and Center (Dec. 22–26, 2025)

Amicus Therapeutics (FOLD) Stock Week Ahead: $14.50 BioMarin Buyout Puts the Deal Spread—and New Filings—Front and Center (Dec. 22–26, 2025)

As of Sunday, December 21, 2025, Amicus Therapeutics, Inc. (NASDAQ: FOLD) is no longer trading like a “typical biotech story stock.” After BioMarin’s all-cash $14.50-per-share takeover agreement, FOLD has effectively become a deal-driven, merger-arbitrage name—meaning next week’s action is likely to hinge less on quarterly fundamentals and more on the probability, timing, and conditions of closing. SEC+1 FOLD last traded around $14.18 (near the offer price), reflecting how quickly the market repriced the shares after the announcement. Investors.com Below is the week-ahead playbook: the latest news as of 21.12.2025, what Wall Street is saying, and the specific catalysts that could
22 December 2025
······
1 2 3 4 5 … 10

Stock Market Today

Wall Street Feels the Heat (and Thrill): Fed Cuts, Tariffs & Mega-Mergers Set NYSE Buzz

Stock Market Today 07.02.2026

7 February 2026
LIVEMarkets rolling coverageStarted: February 7, 2026, 12:00 AM ESTUpdated: February 7, 2026, 12:31 AM EST Dollar Dips as Stocks Rally and US Data Influences Fed Rate Expectations February 7, 2026, 12:18 AM EST. The **dollar index** fell 0.17%, pressured by a rebound in equity markets reducing demand for the safe-haven currency. Weaker-than-expected U.S. labor market data raised the odds of a Fed rate cut to 18% for March, though consumer sentiment improved to a six-month high, limiting losses. Hawkish comments from Atlanta Fed's Raphael Bostic emphasized maintaining restrictive monetary policy. The dollar faces medium-term weakness amid expectations for rate cuts
Seagate (STX) stock jumps nearly 6% as Citi hikes target — what to watch next week

Seagate (STX) stock jumps nearly 6% as Citi hikes target — what to watch next week

7 February 2026
Seagate shares rose 5.9% to $429.32 Friday after Citigroup raised its price target to $480 and reiterated a buy rating. The gain ended a two-day slide but left the stock 6.6% below its Feb. 3 high. CEO Dave Mosley sold 20,000 shares on Feb. 2 under a pre-arranged plan, SEC filings show. U.S. jobs and inflation data next week are seen as key tests for tech stocks.
Cummins (CMI) stock price rebounds after earnings whipsaw as investors eye data-center power demand

Cummins (CMI) stock price rebounds after earnings whipsaw as investors eye data-center power demand

7 February 2026
Cummins shares jumped 6.8% to $577.73 Friday, recovering from a nearly 9% post-earnings drop the day before. The company reported Q4 revenue up 1% to $8.54 billion, took a $218 million charge tied to its hydrogen business, and guided for 2026 EBITDA of 17–18% of sales. Demand for data center generators offset weakness in North American truck markets. Analyst reaction was mixed; Truist raised its price target.
Corning stock hits first record close since 2000 as jobs, CPI data loom

Corning stock hits first record close since 2000 as jobs, CPI data loom

7 February 2026
Corning shares surged 8.3% to $122.16 Friday, their highest close since the dot-com era, after Meta agreed to buy up to $6 billion in fiber-optic cables. The stock is up 40% since late 2025, fueled by strong first-quarter guidance and AI data-center demand. Insiders sold shares following the rally, SEC filings show. Investors await next week’s U.S. jobs and inflation data for rate signals.
Go toTop